Multipl Sklerozda Sistemik Otoantikor Pozitifliğinin Oligoklonal Band Varlığı ve Özürlülük ile İlişkisi

Amaç: Rölapsing remiting multipl skleroz (RRMS) hastalarında sık gözlenen sistemik otoantikorlann sıklığının ve oligoklonal band (OKB) ve hastalık şiddeti ile iHşkilerinin belirlenmesi amaçlandı. Gereç ve Yöntem: Otoimmün hastalığı olmayan toplam 150 kesin RRMS hastası ve 150 sağlıklı kontrol çalışmaya alındı ve serumları otoantikor tayini için incelendi. Bulgular: RRMS olgularında anti-tiroid peroksidaz antikoru (anti-TPO) (%20), anti-kardiolipin (AKA) IgG (%22) ve AKA IgM (%24) antikorları sağlıklı kontrollerden belirgin derecede yüksekti (p < 0.001). Yaş, cinsiyet, OKB pozitifliği ve ortalama "expanded disability status scale" (EDSS) skorları açısından otoantikorlu ve otoantikorsuz RRMS olguları arasında fark yoktu. Sonuç: Bulgularımız serum otoantikorlannm hastalık şiddeti ve OKB oluşumu ile ilişkili olmadıklarım ve sadece MS hastalarında otoimmün hastalığa yakalanma riskindeki artışın bir göstergesi olduklarım düşündürmektedir.

Anahtar Kelimeler:

xx

Association of Systemic Autoantibody Positivity with the Presence of Oligoclonal Bands and Disability in Multiple Sclerosis

Objective: We aimed to determine the frequency of common systemic autoantibodies in patients with relapsing remitting multiple sclerosis (RRMS) and their association with the presence ofoligoclonal bands (OCB) and disease severity. Materials and Methods: A total of 150 definite RRMS patients and 150 healthy controls with no autoimmune disease were enrolled and thensera were examined for the presence of autoantibodies. Results: The positivity rates for antithyroid peroxidase antibody (anti-TPO) (20%), anti-cardiolipin (ACA) IgG (22%) and ACAIgM (24%) antibodies were significantly higher than those of the healthy individuals (p<0.001). Age, gender, OCB positivity rates and average expanded disability status scale (EDSS) scoreswere comparable among RRMS patients with and without autoantibodies. Conclusion: Our findings suggest that serum autoantibodies are not significantly associated with disease severityor OCB formation and they are merely indicators of an increased susceptibility to autoimmune disease induction in MS patients.

PDF

___

Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gr0nning M. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
Annunziata P, Lore' F, Venmrini E, Morana P, Guarino E, Borghi S, Guazzi GC. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci 1999; 168: 32-6.
Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694-706.
Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997; 49: 857-861.
Dittel BN. CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun 2008; 22: 421-430.
Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E, Roullet E. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry 2002; 72:647-9.
Idirnan E, Ozakbas S, Dogan Y, Kosehasanogullari G. The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol 2009; 212: 121-4.
Jacob S, Zarei M, Kenton A, Allroggen H. Gluten sensitivity and neuromyelitis optica: two case reports. J Neurol Neurosurg Psychiatry 2005; 76: 1028-30.
Karussis D, Leker R R, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 1998; 44: 629-34.
Koch M, Heersema D, Mostert J, Teelken A, De Keyser J. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. Eur J Neurol 2007; 14: 797-800.
Korn T. Pathophysiology of multiple sclerosis. J Neurol 2008; 255: 2-6.
McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-lb treatment in two patients with multiple sclerosis. Aust NZ J Med 2000; 30:278-9.
Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004; 3: 199¬210.
Munteis E, Cano JF, Flores JA, Martinez-Rodriguez JE, Miret M, Roquer J. Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. Eur J Neurol 2007; 14: 1048-52.
Niederwieser G, Buchinger W, Bonelli RM, Berghold A, Reisecker F, Koltringer P, Archelos JJ. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 2003; 250: 672¬5.
Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006; 180: 50-62.
Rinker Jr 2nd, Trinkaus K, Naismith RT, Cross AH. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology 2007; 69: 68-72.
Salvatore S, Finazzi S, Ghezzi A, Tosi A, Barassi A, Luini C, Bettini B, Zibetti A, Nespoli L, Melzi d'Eril GV. Multiple sclerosis and celiac disease: is there an increased risk? Mult Scler 2004; 10: 711-712.
Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009; 279: 21-5.
Vilisaar J, Wilson M, Niepel G, Blumhardt LD, Constantinescu CS. A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Mult Scler 2005; 11: 378-80.